Editor's Note |

Colchicine:  Comment on “The Colchicine Debacle”

Rita F. Redberg, MD, MSc
JAMA Intern Med. 2013;173(3):185. doi:10.1001/jamainternmed.2013.3093.
Text Size: A A A
Published online


The US drug approval system has 2 important goals: getting safe and effective drugs rapidly to patients and rewarding innovation in the pharmaceutical industry by offering market exclusivity for new drugs. Unfortunately, there are weaknesses in our current system, as illustrated by this article concerning colchicine. Offering market exclusivity in the 21st century for a drug that has been used for the treatment of gout since the 18th century, with randomized control trials confirming this benefit from the 1980s, is not in the public service. A system that allows a drug that has been used for gout for centuries to be classified as a new discovery, with a price increase of 500% and generics forced off the market, is not in our patients' interest. Patients have little recourse unless regulations are changed to avoid allowing centuries-old drugs to become a profit-making vehicle for industry at the expense of access to patients.


Sign In to Access Full Content

Don't have Access?

Register and get free email Table of Contents alerts, saved searches, PowerPoint downloads, CME quizzes, and more

Subscribe for full-text access to content from 1998 forward and a host of useful features

Activate your current subscription (AMA members and current subscribers)

Purchase Online Access to this article for 24 hours

First Page Preview

View Large
First page PDF preview





Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).
Submit a Comment


Some tools below are only available to our subscribers or users with an online account.

Sign In to Access Full Content

Related Content

Customize your page view by dragging & repositioning the boxes below.

See Also...